Lackey Lab Summer 2023 Journal Club

Our focus this summer is on RNA structure analysis methods. We are reading papers to understand analysis methods that quantify how similar two structures are to one another. Specifically, we are focusing on reading papers that describe methods that allow us to identify conserved or enrichment substructures across different RNAs, such as within precursor RNAs with alternatively spliced intron-exon junctions.

We are reading:

Lackey Lab Journal Club: miRNA neural network

Written by Baxton Munn

1/8/22 – miRNAs, aka micro RNAs, exist to silence genes at the mRNA level, eliciting their degradation through binding of their 3’-UTRs or repressing their translation. Previously, it has been reported that miRNAs play an important role in the brain, specifically the hippocampus, where deletion of Dicer, a protein key to the biogenesis of miRNAs, produced improved performance on cognitive tests in test subjects before leading to cell death. Similar studies led to the conclusion that miRNAs control learning and memory, in addition to neurodegeneration. Underscoring such findings, we recently discussed a paper by Malmevik et al. that sought to characterize not the neural miRNAs, but their mRNA targets and the gene networks regulated by such.

By creating an Ago2 construct containing a neural specific promoter and GFP tag, researchers were able to selectively create a GFP-Ago2 protein only in mouse neural cells that could also be the target of RNA immunoprecipitation (RIP). Enrichment of neural specific miRNAs by qPCR confirmed the specificity of this construct, and sequencing of bound miRNAs found some well known transcripts to be incorporated by Ago2, including Snca and Itgb1. The relative enrichment of bound transcripts was analyzed, with 2177 gene targets confirmed by bioinformatic analysis. Of these enriched genes, three (ex. miR-124, miR-125, and let-7) displayed a high degree of binding to Ago2 and conserved binding sites, thus confirming the efficacy of their RIP-seq and construct.

Specifically focusing on miR-124 (which is highly expressed in hippocampal cells), researchers created a new construct, one with what’s called a miR-sponge, theoretically capable of “absorbing” miRNAs and inhibiting their functions. All within the same construct, they performed RIP on GFP-Ago2 and confirmed the specificity of their sponge construct in neural cells and specificity for miR-124 via qPCR. Taking it a step further, they sequenced the sponge RIP samples and analyzed the bound mRNA targets. What they found was a substantial drop in the number of bound transcripts, about 497 less, and that reduced enrichment in Ago2 binding likely accounted for such a drop off in bound transcripts and an increase in mRNA expression level. Among the top gene networks controlled by 300 of the lost 497 transcripts – nerve development, metabolism, and transcription. Finally, to confirm their construct could more broadly be applied to other mRNA networks, researchers inhibited miR-125 (expressed in glial and neural cells) with the same sponge construct, finding it too lost bound transcripts, about 384 out of 2177. Altogether, Malmevik et al. provided key insight into the mouse hippocampal miRNA targetome with an innovative approach that has broad applications for the characterization of miRNA functions and targets.

Lackey Lab Journal Club: Branchpoints brought to you by CoLa-Seq

11/19/21 – In our pre-Thanksgiving journal club we discussed a bioRxiv paper from the Li and Staley laboratories at the University of Chicago. In this work, Zeng and co-authors describe CoLa-Seq (co- transcriptional lariat sequencing). CoLa-Seq is a new technique that detects lariat containing precursor RNAs and splicing by-products to identify branchpoints. The authors call the two lariat containing species they detect with CoLa-Seq NLIs (nascent lariat intermediates) and ELIs (excised lariat introns). To obtain reads corresponding to NLIs and ELIs, the authors enriched for precursor RNAs by isolating chromatin. They further selected RNA in the process of splicing by decapping and degrading linear RNA, leaving only RNA protected by the 2’-5′ lariat linkage. Using CoLa-Seq, Zeng, et al. identified the largest number of branchpoints. In addition, CoLa-Seq provides a technique to continue branchpoint identification in other cell lines and under additional conditions. A reasonable protocol for branchpoint identification is important as, even with this study, many branchpoints remain unmapped. Branchpoint selection is important for recognition of the 3’ splice site and understanding of alternative splicing.

In addition to describing a new technique and documenting an extensive number of branchpoints, Zeng, et al., analyzed their results to make several novel biological insights. They analyze the timing of splicing by measuring the number of nucleotides past the 3’ splice site in NLI reads. One thing that surprised me from their timing data is the variability at the same intron. In addition, they found that splicing can happen in-order, out-of-order and concurrently. These three different splicing modes occur in different ratios in most transcripts. As spliced intermediates are rare and collected from a large population of cells, I wonder how the state of the cell and the level of transcript affect splicing timing and the order of splicing. Interestingly, splicing did not seem to depend on transcription of the downstream exon, even for long introns, as would be expected for the exon-definition model of splicing. Zeng, et al., also used extensive modeling to try and understand what elements control splicing timing and order. As an RNA structure lab, we were most intrigued by the role of GC content in splicing timing! However, as GC content captures both structural and sequence motifs, it is still too early to say what role RNA structure has in regulating splicing. We look forward to seeing the final version of this manuscript in press.

Lackey Lab Journal Club: miRNA miracles

Written by Baxton Munn

11/12/21 – It remains imperative to discover novel ways to treat multiple myeloma (MM), which stands as the second-most frequently diagnosed hematological cancer. Treatments have progressed immensely in recent years, yet patients remain plagued by the recurrence of the disease and drug resistance to therapeutics. Attempts to identify clinical markers are categorized in the Revised MM International Staging System (R-ISS), which has proven reliable yet itself is plagued by the appearance of heterogenous disease courses in patients of the same stage. Papadimitriou, et al. describe a molecular diagnostic marker, miR-181a, that is overexpressed in MM patients, providing valuable prognostic significance, risk stratification, and a reliable prediction of patients’ response to treatment and disease progression.

            Using miRNA-seq and enrichment analysis, the authors pinpointed six miRNA targets that were dysregulated in both their MM cohort and R-ISS cohort. Survival analysis via Kaplan-Meier survival curves and Cox regression analysis discovered the only candidate with a significant association with worse overall and progression-free survivability: miR-181a. GO Ontology analysis documented this miRNA to be enriched in several key biological processes, including B cell apoptosis and response to glucocorticoids. Next, survival analyses were performed to evaluate the prognostic utility of miR-181a via Kaplan-Meier curves and Cox univariate and multivariate regression analysis. The result: high miR-181a levels were associated with a shorter life expectancy in both overall survivability (OS) and cancer specific survivability, confirmed by an independent cohort. Multivariate Cox regression analysis, incorporating variables such as age, gender, LDH, and cytogenetics, further confirmed miR-181a overexpression and its association with post-treatment progression.

Next, researchers evaluated if miR-181a could serve as a co-prognostic indicator of MM along with R-ISS, high-risk cytogenetics, and 1st line therapy response. Indeed, miR-181a proved invaluable in assisting prognosis with all three existing indicators: in combination with R-ISS, it provided better stratification for patients’ survivability; with high-risk cytogenetics, an increase in inferior disease outcome; and with therapy response, it could predict the risk for disease progression and a worse survival outcome. Finally, decision curve analysis (DCA) compared the net benefit of treating patients evaluated for high miR-181a levels/R-ISS, and response to 1st line therapy to those only evaluated for the latter two. Not surprisingly, there was a significant net benefit in treating those with elevated miR-181a levels compared to those not evaluated for it.

To summarize, Papadimitriou, et al. indicated a key miRNA component of MM prognosis that, along with existing markers and indicators, demonstrates value in significantly improving patients’ prognosis, predictability of disease progression, and survivability outcome.

Lackey Lab Journal Club: eToeholds

Written by Edward Mabry

11/5/21– Our ability to solve problems and treat diseases are limited only by our knowledge of the problem, our imagination, and our tools. While previous studies have found ribozymes to alter mRNA, and therefore protein expression, via small molecules or short nucleotide oligomers, they suffer in the ability to detect longer RNA sequences and/or providing significant fold changes in reporter expression. Our lab read a paper on “RNA-responsive elements for eukaryotic translational control”. In this paper, Zhao et al. developed eToeholds as modular regulators for eukaryotic mRNA translational control which can be altered by the presence of a specific trigger RNA. This is a rather astounding tool, as the module itself could be altered, in theory, to any RNA you wish to detect with relatively high specificity (~40-50 base pairs). The eToeholds themselves can be altered not only for detecting specific RNAs, but also at the IRES for optimization in different systems.

One of their most sensitive eToehold designs utilized the CrPV IRES and had pairing between the 8-6 regions on the secondary structure which had an mKate reporter. After additional optimization to reduce basal expression of the modulated RNA, this eToehold design would produce a 16-fold change in protein expression when triggered with the GFP mRNA in HEK293. Test showed that the eToeholds made with a different target in the same IRES design would not mispair to the different targets and another design developed to allow 5’ caps on these modulated RNAs to allow similar levels of sensitivity. However, when IRES systems were changed to human ones such as from hepatitis C, polio virus, or enterovirus 71 with the same eToehold procedure, the sensitives were found to be much weaker to compromise with higher modulated mRNA magnitudes. But, when testing the claims that the eToehold tool could strongly detect infections, cell states, and cell types, the results were significant and supported the value of this tool. One point to add before the conclusion is that this tool specifically works in the cytosol, so nuclear retained RNAs would not be able act as a trigger; however, that still could be used for test to determine nuclear retention. In conclusion, the eToehold switches produced show strong potential to detect and target cells that express specific mRNAs, whether they be viral, endogenous, or exogenous, and have relatively high specificity in doing so such that it could be used either for diagnostics, therapeutics, or research.

Lackey Lab Journal Club: RNA circle of life, connecting splicing and decay

Written by Austin Herbert

This week in journal club we discussed the paper “Nonsense-Mediated RNA Decay is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations” by Cheruiyot et al. Here, the authors conduct a crispr/cas9 knockout based forward genetic screen to identify previously unknown promoters of nonsense-mediated decay. Top hits from this screen included known NMD-associated factors UPF1, SMG6, and RUVBL1, and previously reported splicing factors not typically associated with NMD, SF3B1 and U2AF1. Both SF3B1 and U2AF1 contain reoccurring hotspot mutations involved in different types of cancers and thus were targeted for their unconventional roles in NMD. Cell lines created with these splicing factor hotspot mutations showed a distinct sensitivity to NMD inhibition, as cells exhibited various cancer related phenotypes such as reduced survivability, increased chromosomal aberrations and R-loop formations, and reduction in DNA replication and transcription fork progression speed. This paper sets the ground work for determining the specific interactions between splicing factors and the NMD pathway.

Lackey Lab Journal Club: AGO1 as a transcription factor

Written by Abigail Hatfield

10-22-21: For this week’s journal club, I elected to look at an AGO1 paper that was recently published in J Cell Biol by Acuña, et al. and relevant to many of our lab’s interests in ongoing experiments within our lab. This paper checked a lot of the boxes: timely, discussing argonaute, proposing functional roles for argonaute, utilizing immunocytochemistry, and incorporating large-scale experimental  and historical ChIP-Seq. 

The experiments performed by Acuña, et al. were interesting first and foremost because argonaute has been widely studied for its role in small RNA-mediated post transcriptional processing and in transcriptional gene silencing. However, they propose an alternate function for argonaute-1: estradiol triggered transcription in human cells. They used ChIP and ChIP-Seq on transfected MCF-7 cells to locate and identify ERα binding sites within the cells relative to argonaute-1 (AGO1), which they found in significance. ERα binding motifs were present throughout the cells expressing AGO1, indicating that they are indeed prominently linked in some capacity.

To further interrogate this connection, they treated these AGO1 transfected MCF-7 cells with estradiol. Upon enrichment, signals of AGO1 expression increased greater than MCF-7 cells that were untreated. Additionally, they detected no change in subcellular localization of AGO1 during E2 treatment. To complete their follow-up, they proceeded to knockdown the function of AGO1 to react to E2, showing a marked decrease in ERα activity within the knockdown cells. They were also able to rescue the functionality of these proteins and restore levels of production to near those of endogenous levels. More interestingly, when they conducted their experiments showing that estrogen increased in response to E2’s presence in relation to AGO1, they also found that when they silenced the AGO1’s ability to incorporate RNA, that the relation continued to exist. This implies that AGO1 and ERα are binding together on the chromatin and that it is activating co-transcriptionally. They were also able to demonstrate that AGO1 is preferentially enriched at active transcriptional enhancers. All of this points to the possibility that AGO1 does indeed act in an estrogen-dependent manner as a transcription coactivator, at least as the authors suggest. The most marked criticism of this paper is simply a wish this lab would like to have granted: investigating this same system in the rest of the family of argonaute proteins. 

Equally important as this conclusion, however, is the implication that proteins may harbor multiple and various functions. In the case of this AGO1, miRNA’s were shown to not even be necessary for its binding on chromatin with ERα. Previous studies indicating the importance of AGO1’s interactions with small RNA’s would have and did entirely miss this potential function. This gives rise to a compelling question: how to identify multiple functions of a protein and, more importantly, what determines the significance and impact of any given functions it may have out of multiple? Is AGO1 more important to transcriptional gene silencing or coactivating with ERα? In what ways would you determine the significance and relevance of AGO1’s influence in both of those mechanisms relative to each other? These are questions we may hope to answer soon, and wrestle with our principles of microbiology and genetics in doing so. 

Lackey Lab Journal Club: A Let7 Special

written by Baxton Munn

9-17-21: RNA silencing is a fascinating mechanism in eukaryotes by which the cell’s own RNA regulates the expression of genes at the transcriptional, post-transcriptional, and translational level. These RNA molecules belong to the subclass of small RNAs (sRNAs) and include small-interfering RNAs (siRNAs), micro RNAs (miRNAs), and piwi-interacting RNAs (piRNAs). These sRNA, along with an Argonaute protein, join to form the RNA-induced silencing complex (RISC).

The process by which miRNAs are incorporated into the RNA-induced silencing complex (RISC) was of great interest in our review in the publication “Argonaute-3 activates the let-7a passenger strand microRNA”, published in RNA Biology in 2013. The authors, J. Winters and S. Diederichs, detailed the unusual affinity one of the Argonaute family proteins, Argonaute 3 (Ago3), had for the passenger strand of Let-7a. When miRNAs are synthesized, they are processed into a duplex, consisting of a guide strand and passenger strand. It has been known that the guide strand is the one incorporated into RISC to assist with cleaving target RNA, while the passenger strand is sent for degradation. In addition, Ago3 was thought to be catalytically inactive, overshadowed by its cleavage-inducing family member Argonaute 2 (Ago2). Nevertheless, Winters and Diedrichs found that Ago3 not only incorporated the passenger strand of let-7a, called let-7a-3p, but it was also catalytically activated by this strand.

Analysis by northern blotting, with confirmation from qRT-PCR, confirmed that overexpression of Ago3 led to an increase in the expression of let-7a-3p and an increase in the ratio between passenger strand (let-7a-3p) and guide strand (let-7a-5p). Luciferase assays detailed the overexpression of Ago3 in another crucial way: an increase in let-7a-3p’s silencing activity, as evidenced by a decrease in luciferase expression upon let-7a-3p binding to Ras-related GTP binding protein RAB10. Winters and Diedrichs then created recombinant let-7a by switching its terminal loop with another miRNA, miR-193a, to see if any structural component affected Ago3’s incorporation of the miRNA. The recombinant hairpin loop did not affect incorporation, suggesting the let-7a duplex was responsible for it instead. Next, the authors questioned whether Ago3 would be affected by base-pairing and thermodynamic stability at the 5’ end of let-7a, a property by which the less stable strand is usually incorporated into RISC. However, Ago3 did not significantly increase incorporation of let-7a-3p when mutated strands were co-transfected with it, suggesting a departure from previous knowledge. Finally, the Winters and Diedrichs questioned the domains in Ago3 responsible for incorporating let-7a-3p into RISC, and after co-transfecting constructs of Ago3, chimeric Ago3 (domain swapped with Ago1), and let-7a, they determined by qRT-PCR the binding of let-7a-3p by the PAZ and MID domains, which bind the 5’ and 3’ end of miRNA, respectively.

To conclude, Winters and Diedrichs discovered a novel mechanism by which Argonaute 3, previously thought to be catalytically dead, could be activated by and incorporate a passenger strand of miRNA, let-7a-3p, increasing its expression and silencing activity, while detailing the significance of miRNA structure, stability, and sequence on incorporation into RISC. The implications of this research certainly lead to the possibility of other miRNA passenger strands being utilized to some capacity, though there remains little current research. Another possible candidate for further research is the role Ago3 has in regulating the tumor suppressor abilities of let-7a, which targets RAS and HMGA2. Such findings would shed insight into how RNA silencing can regulate oncogenes or what miRNA dysregulation may implicate.  

Lackey Lab Journal Club: Treating A1AT deficiency liver disease

Written by Edward Mabry

9-10-21 – Alpha-1 antitrypsin deficiency is a genetic disorder which can lead to severe issues in both the lungs and liver, including COPD and liver cirrhosis. However, the current treatments for this disorder are invasive, costly, or limited to those already in life-threatening conditions. In the lab, we recently investigated a paper titled “Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency”. Karadagi et al. experimented with a lipid nanoparticle (LNP) that delivers a modified mRNA payload to hepatocytes in the liver for A1AT protein as a potential treatment. The effectiveness of the treatment was tested extensively in patient hepatocytes, a wild type mouse model, and even a NSG PiZ mouse model. An elastase activity assay was utilized to show an increase to the expression of the inhibitory A1AT protein secretion into the media or serum of the mice. The localization of the A1AT protein, mRNA, and even potential cellular stress caused by the treatment were all tested and verified. The LNP mRNA was confirmed to last at least 48 hours, enter the cell, had produced and exported A1AT protein, and did not cause cellular stress or damage along the way. While the treatment seemed to make a large impact in both patient hepatocytes and the wild-type mouse model compared to samples which only received the LNP alone, the NSG PiZ mice did not show significant result in the elastin activity assay. The paper explained that the reason it had not expressed a strong increase in A1AT despite having the functional mRNA present as visualized by the RNAscope (in Figure 5c) was that A1AT likely has a down regulation mechanism; however, they did not test into this further as it was “outside the scope of the paper”. In conclusion, while this modified messenger RNA did not make a significant increase to A1AT such that it showed more than an increased inhibitory trend in the NSG PiZ mice, it does show promise for a controlled protein expression system regulated via RNA.


Lackey Lab Journal Club: PolyA tail metabolism

Written by Austin Herbert

8/27/21 – The poly-adenylation of RNAs is a ubiquitous mechanism in all eukaryotes. It facilitates the cellular localization of transcripts and contributes to transcript fate. We discussed a recent publication by Tudek and Krawczyk et al. on poly-A tail metabolism using yeast (Saccharomyces cerevisiae) as a model organism. Using functional studies, Tudek and colleagues were able to measure the effects of knocking out poly-adenylation enzymes via direct RNA sequencing on a nanopore platform. They illustrated the efficacy of this newly developed direct RNA sequencing platform in comparison to conventional methods of RNA sequencing and then used it to assess poly-A metabolism under different conditions. They demonstrated that there is no significant difference between the length of poly-A tails in non-coding RNAs (ncRNAs) and coding mRNAs. They also demonstrated that the level of expression played a significant role in the poly-adenylation of a transcript. Highly expressed genes were rapidly exported from the nucleus and had their poly-A tails metabolized via PAN2/3, while genes with lower expression levels were slowly exported from the nucleus and had their poly-A tails metabolized via CCR4-NOT. Overall, I would have liked to see this group evaluate potential intrinsic factors of the mRNAs that influence which enzyme and poly-A metabolic pathways determine its fate.